NodThera’s pill lowered inflammation. The scales stayed put.

Now called Rezera, NodThera is taking an oral inflammation inhibitor toward a planned Phase 3 trial in peripheral artery disease. Its latest human results offer a useful lesson in what a promising drug actually proves.